A novel disulfidptosis-related gene signature predicts overall survival of glioblastoma patients

References

• Ostrom QT, Gittleman H, Liao P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 16(Suppl. 4), iv1–iv63 (2014).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Liu X, Nie L, Zhang Y et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat. Cell Biol. 25(3), 404–414 (2023).
   PubMed Web of Science ®Google Scholar
• Bonifacio VDB, Pereira SA, Serpa J, Vicente JB. Cysteine metabolic circuitries: druggable targets in cancer. Br. J. Cancer 124(5), 862–879 (2021).
   PubMed Web of Science ®Google Scholar
• Lim JKM, Delaidelli A, Minaker SW et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc. Natl Acad. Sci. USA 116(19), 9433–9442 (2019).
   PubMed Web of Science ®Google Scholar
• Li S, Lu Z, Sun R et al. The Role of SLC7A11 in cancer: friend or foe? Cancers (Basel) 14(13), 3059 (2022).
   PubMed Web of Science ®Google Scholar
• Tran TO, Vo TH, Lam LHT, Le NQK. ALDH2 as a potential stem cell-related biomarker in lung adenocarcinoma: comprehensive multi-omics analysis. Comput. Struct. Biotechnol. J. 21, 1921–1929 (2023).
   PubMed Web of Science ®Google Scholar
• Dang HH, Ta HDK, Nguyen TTT et al. Prospective role and immunotherapeutic targets of sideroflexin protein family in lung adenocarcinoma: evidence from bioinformatics validation. Funct. Integr. Genomics 22(5), 1057–1072 (2022).
   PubMed Web of Science ®Google Scholar
• Pattwell SS, Arora S, Cimino PJ et al. A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways. Nat. Commun. 11(1), 2977 (2020).
   PubMed Web of Science ®Google Scholar
• Li M, Ruan B, Wei J et al. ACYP2 contributes to malignant progression of glioma through promoting Ca(2+) efflux and subsequently activating c-Myc and STAT3 signals. J. Exp. Clin. Cancer Res. 39(1), 106 (2020).
   PubMed Web of Science ®Google Scholar
• Jiang K, Yao G, Hu L et al. MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling. Cell Death Dis. 11(4), 230 (2020).
   PubMed Web of Science ®Google Scholar
• Chipman ME, Wang Z, Sun D, Pedraza AM, Bale TA, Parada LF. Tumor progression is independent of tumor-associated macrophages in cell lineage-based mouse models of glioblastoma. Proc. Natl Acad. Sci. USA 120(16), e2222084120 (2023).
   PubMed Web of Science ®Google Scholar
• Qi D, Geng Y, Cardenas J et al. Transcriptomic analyses of patient peripheral blood with hemoglobin depletion reveal glioblastoma biomarkers. NPJ Genom Med. 8(1), 2 (2023).
   PubMed Web of Science ®Google Scholar
• Chang Z, Huang R, Fu W et al. The Construction and Analysis of ceRNA Network and Patterns of Immune Infiltration in Colon Adenocarcinoma Metastasis. Front Cell Dev. Biol. 8, 688 (2020).
   PubMed Web of Science ®Google Scholar
• Huang R, Meng T, Chen R et al. The construction and analysis of tumor-infiltrating immune cell and ceRNA networks in recurrent soft tissue sarcoma. Aging (Albany NY) 11(22), 10116–10143 (2019).
   PubMedGoogle Scholar
• Lu J, Li H, Chen Z et al. Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma. Cancer Cell Int. 19, 265 (2019).
   PubMed Web of Science ®Google Scholar
• Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, MillerWHJr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 27(Suppl. 2), S87–S97 (2020).
   PubMedGoogle Scholar
• Wang H, Zhou H, Xu J et al. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Lett. 496, 134–143 (2021).
   PubMed Web of Science ®Google Scholar
• Lvu W, Fei X, Chen C, Zhang B. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma. Biosci. Rep. 40(8), BSR20201037 (2020).
   PubMedGoogle Scholar
• Aragam KG, Chaffin M, Levinson RT et al. Phenotypic refinement of heart failure in a national biobank facilitates genetic discovery. Circulation 139(4), 489–501 (2018).
   PubMed Web of Science ®Google Scholar
• Han M, Wang S, Fritah S et al. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/beta-catenin signalling. Brain 143(2), 512–530 (2020).
   PubMed Web of Science ®Google Scholar
• Rezaei O, Tamizkar KH, Sharifi G, Taheri M, Ghafouri-Fard S. Emerging role of long non-coding RNAs in the pathobiology of glioblastoma. Front Oncol. 10, 625884 (2020).
   PubMed Web of Science ®Google Scholar
• Ke L, Li S, Cui H. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. BMC Cancer 22(1), 1185 (2022).
   PubMed Web of Science ®Google Scholar
• Cristescu R, Aurora-Garg D, Albright A et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J. Immunother. Cancer 10(1), e003091 (2022).
   PubMed Web of Science ®Google Scholar
• Xu K, Zhang Y, Yan Z et al. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis. Front Immunol. 14, 1205250 (2023).
   PubMed Web of Science ®Google Scholar
• Champeaux-Depond C, Jecko V, Weller J, Constantinou P, Tuppin P, Metellus P. Newly diagnosed high-grade glioma surgery with carmustine wafers implantation. a long-term nationwide retrospective study. World Neurosurg. 173, e778–e786 (2023).
   PubMed Web of Science ®Google Scholar
• Zhao YH, Wang ZF, Pan ZY et al. A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: time to consider the timing of reoperation. Front Neurol. 10, 286 (2019).
   PubMed Web of Science ®Google Scholar
• Schittenhelm J, Krischker N, Gepfner-Tuma I et al. Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas. Brain Pathol. 29(3), 321–324 (2019).
   PubMed Web of Science ®Google Scholar
• Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103(34), 12873–12878 (2006).
   PubMed Web of Science ®Google Scholar
• Aydin B, Patil M, Bekele N, Wolff JE. Vincristine in high-grade glioma. Anticancer Res. 30(6), 2303–2310 (2010).
   PubMed Web of Science ®Google Scholar